Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERGE phase 3 trial of claseprubart in generalized myasthenia gravis
MOH_2026-10-18_017095Phase 3Not yet recruiting
- Sponsor
- Dianthus Therapeutics
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of claseprubart in myasthenia gravis (MG) (3 arms), sponsored by Dianthus Therapeutics. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
claseprubart
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on MOH_2026-10-18_017095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-10-18_017095.